TMJ NextGen Pilot Study to Treat Subjects With Bruxism

Bruxism Clinical Trial

Official title:

A Pilot Study of the TMJ NextGeneration Compared to the DSG Relaxer for Reduction in Nocturnal Bruxism Episodes in Subjects Diagnosed With Sleep Bruxism

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02446288
• Other study ID #: TMJ-1003
• Status: Not yet recruiting
• Phase: N/A
• First received: May 12, 2015
• Last updated: May 13, 2015
• Start date: June 2015
• Est. completion date: November 2015

Study information

• Verified date: May 2015
• Source: Cardiox Corporation
• Contact: Simon Blackburn, CCRA
• Phone: 614.323.7034
• Email: simonblackburn[@]cardiox.com
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study is an open-label, prospective, multicenter, randomized, two treatment parallel, comparison study of the TMJ NextGeneration and DSG Relaxer in the reduction of nocturnal bruxism episodes in subjects diagnosed with sleep bruxism.

Description:

The study will be conducted at multiple study centers in the U.S. Subjects will be enrolled in the trial for a period of 44 days. The study will consist of a screening period lasting up to 30 days, a device fitting period of 14 days, and a treatment period lasting 30 days. Subjects will visit the clinic three times during the screening period, followed by visits at Day 1, Day 14, and Day 44 of the study. Subjects will visit the sleep center once during the screening period (Day -1) and once during the treatment period (Day 43).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: November 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects at least 18 years of age;

2. Subject has had a diagnosis of sleep bruxism confirmed within the past 30 days;

3. Subject has an average of = 1.25 bruxism episodes per hour of sleep based on two nights of screening Bruxoff™ evaluations;

4. Subject is able to read and understand the ICF and has voluntarily provided written informed consent;

5. Subject has a minimum of 26 remaining teeth;

6. Subject has an average of = 1.25 bruxism episodes per hour of sleep based on the single-night screening sleep PSG evaluations.

Exclusion Criteria:

1. Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol;

2. Subject has a significant respiratory disease that actively requires treatment;

3. Subject is taking antidepressant medication;

4. Subject has a significant sleep disorder that actively requires treatment, in addition to bruxism;

5. Subject is undergoing treatment for sleep apnea;

6. Subjects diagnosed with rheumatoid arthritis, osteoarthritis, osteoarthrosis, or another connective tissue disorder of the head/neck region;

7. Subjects who have had direct trauma to the jaw;

8. Subjects who have used an occlusal appliance to treat a TMD within the previous six months;

9. Subjects who have had prior TMJ or ear surgery;

10. Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified;

11. Subjects with visible or congenital ear deformity as observed on targeted physical exam that does not allow for fitting of the study device;

12. Subjects who have taken a narcotic pain medication in the last seven days prior to Day 1 of the study;

13. Subjects who have a history of chronic ear pain unrelated to TMJ;

14. Subjects who have a history of ear drainage in the past six months;

15. Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam;

16. Subjects whom the investigator believes may not be an appropriate candidate for an intra-oral splint due to missing or poor quality dentition or untreated pain of dental origin (pulpal pain, pericoronitis of wisdom teeth, or similar conditions).

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bruxism

Intervention

Device:
• TMJ Next Generation

• DSG Relaxer

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Cardiox Corporation	TMJ Health

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective of this study is to determine the effectiveness of the TMJ NextGeneration to reduce nocturnal bruxism episodes in subjects experiencing sleep bruxism as determined by polysomnography.		30 days	No
Secondary	The secondary objective of this study is to further establish the safety of the TMJ NextGeneration device as determined by adverse events.		30 days	Yes